Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 6 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Adjuvant chemotherapy declining in men undergoing retroperitoneal lymph node dissection

26 Jun 2020

The last decade has seen minimal use of adjuvant chemotherapy following primary retroperitoneal lymph node dissection (RPLND), according to a recent study. The majority (81 percent) of men with pathological stage (PS)-II disease have been cured with RPLND alone and have been able to avoid chemotherapy.

Patients who underwent primary RPLND between January 2007 and December 2017 were identified via retrospective review of the Indiana University testis cancer database. The authors contacted patients and providers to obtain information regarding adjuvant therapy, recurrence, and survival. Recurrence-free survival was the primary endpoint, and survival differences were assessed using Kaplan-Meier curves stratified by PS, template of dissection, and use of adjuvant chemotherapy.

Of the 274 men included in the study, 214 (78 percent) presented with clinical stage I disease. Modified unilateral and bilateral template dissections were performed in 257 (94 percent) and 17 (6 percent) patients, respectively. Overall, 148 (54 percent) men had PS I and 126 (46 percent) PS-II disease.

Adjuvant chemotherapy was given to 13 patients (10 percent) with PS-II disease. Thirty-three (23 percent) men had recurrence over a median follow-up of 55 months.

Twenty-one (19 percent) of the 113 patients with PS-II disease who did not receive chemotherapy experienced disease relapse. Moreover, 81 percent were cured with surgery alone and never had recurrence. The primary endpoint did not differ between modified and bilateral template dissections.

“Modified unilateral template dissection provided excellent oncologic control while minimizing morbidity,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 6 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.